Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration Is Prevented Via Cannabinoid Receptor 2 Agonism In Vitro

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Nov 25

PMID 38004445

Authors

John Noone

Mary F Rooney

Marilena Karavyraki

Andrew Yates

Saoirse E OSullivan

Richard K Porter

Affiliations

Soon will be listed here.

Abstract

Cachexia syndrome, leading to reduced skeletal muscle and fat mass, is highly prevalent in cancer patients, resulting in further negative implications for these patients. To date, there is no approved therapy for cachexia syndrome. The objective of this study was to establish an in vitro model of cancer cachexia in mature human skeletal muscle myotubes, with the intention of exploiting the cell model to assess potential cachexia therapeutics, specifically cannabinoid related drugs. Having cultured and differentiated primary human muscle myoblasts to mature myotubes, we successfully established two cancer cachexia models using conditioned media (CM) from human colon adenocarcinoma (SW480) and from non-small-cell lung carcinoma (H1299) cultured cells. The cancer-CM-induced extensive myotube degeneration, demonstrated by a significant reduction in mature myotube diameter, which progressed over the period studied. Myotube degeneration is a characteristic feature of cancer cachexia and was used in this study as an index of cachexia. Expression of cannabinoid 1 and 2 receptors (CBR and CBR) was confirmed in the mature human skeletal muscle myotubes. Subsequently, the effect of cannabinoid compounds on this myotube degeneration were assessed. Tetrahydrocannabinol (THC), a partial CBR/CBR agonist, and JWH133, a selective CBR agonist, proved efficacious in protecting mature human myotubes from the deleterious effects of both (SW480 and H1299) cancer cachexia conditions. ART27.13, a full, peripherally selective CBR/CBR agonist, currently being trialled in cancer cachexia (IRAS ID 278450, REC 20/NE/0198), was also significantly protective against myotube degeneration in both (SW480 and H1299) cancer cachexia conditions. Furthermore, the addition of the CBR antagonist AM630, but not the CBR antagonist Rimonabant, abolished the protective effect of ART27.13. In short, we have established a convenient and robust in vitro model of cancer-induced human skeletal muscle cachexia. The data obtained using the model demonstrate the therapeutic potential of ART27.13 in cancer-induced cachexia prevention and provides evidence indicating that this effect is via CBR, and not CBR.

References

Esposito I, Proto M, Gazzerro P, Laezza C, Miele C, Alberobello A . The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol. 2008; 74(6):1678-86. DOI: 10.1124/mol.108.049205. View

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W . Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the.... J Clin Oncol. 2006; 24(21):3394-400. DOI: 10.1200/JCO.2005.05.1847. View

OSullivan S, Yates A, Porter R . The Peripheral Cannabinoid Receptor Type 1 (CB) as a Molecular Target for Modulating Body Weight in Man. Molecules. 2021; 26(20). PMC: 8538448. DOI: 10.3390/molecules26206178. View

Haddad M . The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells. Pathophysiology. 2022; 28(4):457-470. PMC: 8830471. DOI: 10.3390/pathophysiology28040029. View

Pertwee R . Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2006; (168):1-51. DOI: 10.1007/3-540-26573-2_1. View

Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View

Ferrer M, Anthony T, Ayres J, Biffi G, Brown J, Caan B . Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023; 186(9):1824-1845. PMC: 11059056. DOI: 10.1016/j.cell.2023.03.028. View

Crespillo A, Suarez J, Bermudez-Silva F, Rivera P, Vida M, Alonso M . Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J. 2010; 433(1):175-85. DOI: 10.1042/BJ20100751. View

10.

Costiniuk C, Mills E, Cooper C . Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol. 2008; 22(4):376-80. PMC: 2662895. DOI: 10.1155/2008/725702. View

11.

Wu C, Zhu M, Lu Z, Zhang Y, Li L, Li N . L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis. Nutr Metab (Lond). 2021; 18(1):98. PMC: 8559414. DOI: 10.1186/s12986-021-00623-7. View

12.

Pertwee R . Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006; 147 Suppl 1:S163-71. PMC: 1760722. DOI: 10.1038/sj.bjp.0706406. View

13.

Zhang M, Zhang M, Wang L, Yu T, Jiang S, Jiang P . Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Life Sci. 2019; 230:55-67. DOI: 10.1016/j.lfs.2019.05.056. View

14.

Nagappan A, Shin J, Jung M . Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Int J Mol Sci. 2019; 20(9). PMC: 6540410. DOI: 10.3390/ijms20092109. View

15.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

16.

Aversa Z, Costelli P, Muscaritoli M . Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017; 9(5):369-382. PMC: 5424865. DOI: 10.1177/1758834017698643. View

17.

Iannotti F, Pagano E, Guardiola O, Adinolfi S, Saccone V, Consalvi S . Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nat Commun. 2018; 9(1):3950. PMC: 6160489. DOI: 10.1038/s41467-018-06267-1. View

18.

Levitt D, Adler K, Simon L . HEMA 3 Staining: A Simple Alternative for the Assessment of Myoblast Differentiation. Curr Protoc Stem Cell Biol. 2019; 51(1):e101. PMC: 7254186. DOI: 10.1002/cpsc.101. View

19.

Dalle S, Schouten M, Meeus G, Slagmolen L, Koppo K . Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity. J Cell Physiol. 2022; 237(9):3517-3540. DOI: 10.1002/jcp.30837. View

20.

Young L, Sung J, Stacey G, Masters J . Detection of Mycoplasma in cell cultures. Nat Protoc. 2010; 5(5):929-34. DOI: 10.1038/nprot.2010.43. View